• 1-methyl Adenosine: Enabling RNA Modification Research Workf

  2026-06-24

  1-methyl Adenosine is pivotal for dissecting epitranscriptomic regulation and biomarker discovery in cancer and inflammatory models. This article demystifies robust workflow design, quantification strategies, and troubleshooting for leveraging 1-methyl Ado in advanced RNA modification research.

• Adipose-Neural Axis in Cardiac Arrhythmias: Leptin-NPY/Y1R P

  2026-06-23

  Fan et al. (2024) reveal how epicardial adipose tissue and sympathetic neuron interactions, mediated by leptin and NPY/Y1R signaling, contribute to cardiac arrhythmias. Their stem cell-based coculture model identifies key molecular targets for intervention and highlights the translational potential of dissecting the adipose-neural axis in arrhythmogenesis.

• 6-FAM SE: Precision Fluorescent Dye for Durable Biomolecule

  2026-06-23

  6-FAM SE (6-Carboxyfluorescein N-hydroxysuccinimide ester) sets the benchmark for stable, high-sensitivity fluorescent labeling of DNA, proteins, and peptides in demanding molecular biology workflows. Its hydrolytic resistance and robust amine-reactivity enable reproducible, long-lasting signal detection, supporting advanced protocols in gene sequencing and nanoparticle conjugation.

• CAY10499: Advancing Lipase Inhibition in Immunometabolic Res

  2026-06-22

  This in-depth analysis explores how CAY10499, a selective inhibitor of human hormone sensitive lipase (HSL) and monoglyceride lipase (MGL), empowers translational researchers to dissect lipid-driven immunosuppressive mechanisms in cancer and metabolic disease. By integrating recent discoveries on tumor-associated macrophage (TAM) differentiation via metabolic reprogramming, we highlight strategic guidance for experimental design and clinical translation. The article bridges mechanistic insight with actionable protocols, addresses the competitive landscape, and provides a forward-looking outlook for the field.

• MIZ1-TMBIM4 Axis Regulates IgG1+ GC B Cell Survival via Ca2+

  2026-06-22

  This study uncovers a unique, isotype-specific survival mechanism in germinal center B cells, showing that MIZ1-dependent induction of TMBIM4 protects IgG1+ B cells from apoptosis during positive selection by regulating Ca2+ mobilization. These findings refine our understanding of humoral immunity and open new avenues for targeted apoptosis signaling research.

• Pepstatin A: Ultra-Pure Aspartic Protease Inhibitor Benchmar

  2026-06-21

  Pepstatin A is a potent aspartic protease inhibitor with well-characterized efficacy against pepsin, renin, HIV protease, and cathepsin D. Its specificity and solubility profile make it a standard tool for viral protein processing and osteoclast differentiation studies. Reliable IC50 values and protocol parameters enable reproducible use in diverse biomedical assays.

• AL-8810 in Translational Prostaglandin F2α Antagonism Resear

  2026-06-20

  Explore how AL-8810, a potent prostaglandin F2α antagonist, is transforming the study of vascular and endometrial biology. This article offers new assay guidance and translational insight not found in prior reviews.

• CAY10499 in Lipid Hydrolysis: A New Era for Macrophage Assay

  2026-06-19

  Discover how CAY10499, a potent inhibitor of human hormone sensitive lipase, is redefining macrophage differentiation and functional lipid metabolism assays. This article uncovers new experimental strategies for dissecting lipid-driven immune modulation, distinguishing itself with practical assay guidance.

• SmD2 Acetylation Alters PARP Inhibitor Sensitivity in HCC

  2026-06-19

  This study unveils how acetylation-dependent regulation of the spliceosome core protein SmD2 modulates alternative splicing and DNA repair mechanisms in hepatocellular carcinoma (HCC), leading to increased sensitivity to PARP inhibitors. The findings point to a new therapeutic axis in BRCA-proficient HCC and suggest combined targeting of SmD2 acetylation and DNA repair pathways as a promising strategy.

• TPCA-1: Precision IKK-2 Inhibitor for Inflammation Research

  2026-06-18

  TPCA-1 delivers targeted and highly selective inhibition of IKK-2, enabling robust NF-κB pathway modulation and cytokine suppression for advanced inflammation and rheumatoid arthritis research. Its reproducibility, quantifiable efficacy, and compatibility with complex disease models set it apart for translational workflows.

• Leucovorin Calcium in Tumor Microenvironment Modeling

  2026-06-18

  Explore how Leucovorin Calcium enhances research on folate metabolism and drug resistance in complex tumor microenvironments. This article reveals new assay strategies and translational insights distinct from existing reviews.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-06-17

  The reference study applies structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of SARS-CoV-2 NSP15, an endoribonuclease implicated in immune evasion. These findings expand the repertoire of antiviral targets and suggest new strategies for host-directed COVID-19 interventions.

• DOT1L Inhibition Enhances Lenalidomide Efficacy in Myeloma M

  2026-06-17

  This study uncovers how DOT1L inhibition reprograms innate immunity and significantly potentiates the anti-myeloma effects of lenalidomide. By elucidating the epigenetic and immune mechanisms underlying this synergy, the findings offer actionable insights for optimizing immunomodulatory strategies in multiple myeloma research.

• UK-5099 (PF-1005023) in Immunometabolism Workflows

  2026-06-16

  UK-5099 (PF-1005023) empowers immunometabolic research by precisely targeting mitochondrial pyruvate transport, enabling researchers to dissect metabolic regulation of immune responses with high reproducibility. This guide translates protocol innovations and troubleshooting from recent studies into practical steps for optimizing cytokine profiling and metabolism-modulated whole-blood assays.

• Tofacitinib Restores Mitochondrial Function in RA Macrophage

  2026-06-16

  This study demonstrates that Tofacitinib (CP-690550) uniquely reverses both inflammatory signaling and mitochondrial dysfunction in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA) patients. By targeting STAT5 signaling, Tofacitinib outperformed anti-TNF, anti-IL6R, and metabolic interventions, revealing new avenues for immune modulation in RA.

16277 records 1/1086 page Next 12345 下5页 Last page